CN108175764B - 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 - Google Patents
一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 Download PDFInfo
- Publication number
- CN108175764B CN108175764B CN201711378024.0A CN201711378024A CN108175764B CN 108175764 B CN108175764 B CN 108175764B CN 201711378024 A CN201711378024 A CN 201711378024A CN 108175764 B CN108175764 B CN 108175764B
- Authority
- CN
- China
- Prior art keywords
- anhydrous
- beclomethasone dipropionate
- water
- insoluble
- dipropionate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title claims abstract description 128
- 229950000210 beclometasone dipropionate Drugs 0.000 title claims abstract description 118
- 239000000725 suspension Substances 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000000843 powder Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 72
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000003960 organic solvent Substances 0.000 claims abstract description 31
- 239000000243 solution Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 20
- 230000001954 sterilising effect Effects 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 238000001914 filtration Methods 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000011049 filling Methods 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 239000008174 sterile solution Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 21
- 239000000443 aerosol Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 12
- 238000009826 distribution Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 4
- 239000000337 buffer salt Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 3
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 2
- HJRDNARELSKHEF-CLFAGFIQSA-N 2-[2-[(z)-octadec-9-enoyl]oxyethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC\C=C/CCCCCCCC HJRDNARELSKHEF-CLFAGFIQSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229940072958 tetrahydrofurfuryl oleate Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007971 pharmaceutical suspension Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 46
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 16
- 238000000889 atomisation Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 230000006837 decompression Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- QBFXBDUCRNGHSA-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(methylamino)pentan-1-one Chemical compound FC1=CC=C(C=C1)C(C(CCC)NC)=O QBFXBDUCRNGHSA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- QHQJZIXSVLFOHD-LYRZEVDOSA-N [2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O QHQJZIXSVLFOHD-LYRZEVDOSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940038482 beclomethasone dipropionate monohydrate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Abstract
Description
组分 | 制剂总量 |
无水二丙酸倍氯米松 | 50g |
无水乙醇 | 500ml |
检测项 | 原料 | 实施例2 |
水分 | 0.3% | 0.3% |
乙醇残留 | 79ppm | 56ppm |
检测项 | 原料 | 实施例2 |
最大单杂(已知) | 0.13% | 0.12% |
最大单杂(未知) | 0.07% | 0.07% |
总杂 | 0.29% | 0.28% |
组分 | 制剂总量 |
无水二丙酸倍氯米松 | 50g |
无水乙醇 | 500ml |
检测项 | 原料 | 实施例3 |
水分 | 0.3% | 3.5% |
乙醇残留 | 79ppm | 65ppm |
组分 | 制剂总量 |
无水二丙酸倍氯米松 | 50g |
二氧六环 | 500ml |
检测项 | 原料 | 实施例4 |
水分 | 0.3% | 0.3% |
二氧六环残留 | 7ppm | 6ppm |
粒径d(v,0.1) | 粒径d(v,0.5) | 粒径d(v,0.9) |
0.89μm | 2.11μm | 4.34μm |
检测项目 | 实施例5 | 市售原研(2ml:0.8mg) |
FPF[%] | 28.7 | 29.4 |
FPD[μg] | 140.0 | 143.6 |
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711378024.0A CN108175764B (zh) | 2017-12-19 | 2017-12-19 | 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711378024.0A CN108175764B (zh) | 2017-12-19 | 2017-12-19 | 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108175764A CN108175764A (zh) | 2018-06-19 |
CN108175764B true CN108175764B (zh) | 2020-02-21 |
Family
ID=62546496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711378024.0A Active CN108175764B (zh) | 2017-12-19 | 2017-12-19 | 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108175764B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110339063B (zh) * | 2019-08-12 | 2022-01-18 | 浙江福瑞喜药业有限公司 | 一种非终端灭菌处理的无菌混悬液药剂制备工艺 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1326341A (zh) * | 1998-11-13 | 2001-12-12 | 杰格研究股份公司 | 用于吸入给药的干粉 |
CN104739811A (zh) * | 2015-02-27 | 2015-07-01 | 上海臣邦医药科技有限公司 | 一种糖皮质激素雾化吸入混悬液及其制备方法 |
WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
CN106063778A (zh) * | 2015-04-21 | 2016-11-02 | 北京化工大学 | 一种丙酸倍氯米松透明水相纳米分散体的制备方法 |
-
2017
- 2017-12-19 CN CN201711378024.0A patent/CN108175764B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1326341A (zh) * | 1998-11-13 | 2001-12-12 | 杰格研究股份公司 | 用于吸入给药的干粉 |
CN104739811A (zh) * | 2015-02-27 | 2015-07-01 | 上海臣邦医药科技有限公司 | 一种糖皮质激素雾化吸入混悬液及其制备方法 |
WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
CN106063778A (zh) * | 2015-04-21 | 2016-11-02 | 北京化工大学 | 一种丙酸倍氯米松透明水相纳米分散体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108175764A (zh) | 2018-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100361413B1 (ko) | 플루티카손 프로피오네이트 제제 | |
CN102319209B (zh) | 鼻用药物制剂和使用方法 | |
CN105101955B (zh) | 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物 | |
BRPI0304821B1 (pt) | processo de preparação de uma suspensão estéril de partículas de corticosteróide para administração por inalação | |
CN1805729B (zh) | 鼻用药物制剂和使用方法 | |
US6187765B1 (en) | Mometasone furoate suspensions for nebulization | |
EA012388B1 (ru) | Водные суспензии циклесонида для аэрозольного распыления | |
CA2305256C (en) | Mometasone furoate suspensions for nebulization | |
CN108175763B (zh) | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 | |
CN108175764B (zh) | 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 | |
JP6919093B2 (ja) | 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも1種の乾燥粉末を含む組成物 | |
US6462090B1 (en) | Formulations for detecting asthma | |
WO2022105877A1 (zh) | 包含银杏内酯类成分的药物组合物和制剂及其用途 | |
RU2611665C2 (ru) | Улучшенный состав суспензии кортикостероида для ингаляционного введения | |
CN113350323A (zh) | 一种用于抑制冠状病毒的吸入剂及其制备方法和应用 | |
CN113940925B (zh) | 一种雾化吸入用甲磺酸阿比多尔冻干剂 | |
CN107510687B (zh) | 一种供雾化用含有福莫特罗和布地奈德的吸入混悬液及其制备方法 | |
CN114515279A (zh) | 一种安立生坦雾化吸入溶液及其制备方法 | |
CN113133993A (zh) | 无菌吸入用混悬制剂及其制备方法 | |
CN106999599A (zh) | 帕洛诺司琼气雾制剂及其用途 | |
CN114073684A (zh) | 三苯乙酸维兰特罗吸入溶液及其制备方法 | |
CN116942607A (zh) | 一种西罗莫司混悬液 | |
CN114642656A (zh) | 一种吸入用尼达尼布溶液及其制备方法 | |
CN117860712A (zh) | 一种吸入用氨糖组合物及其制备方法和其应用 | |
CN115137713A (zh) | 一种两性霉素b雾化吸入制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Building 10, biomedical industrial park, 218 Sangtian street, Suzhou Industrial Park, Suzhou area, Suzhou pilot Free Trade Zone, 215000, Jiangsu Province Patentee after: Ruisi Pharmaceutical (Suzhou) Co.,Ltd. Address before: 215123 E143 unit, 2 floor, North Tower, A1 building, 218 Biological Park, Xing Su District, Suzhou, Jiangsu. Patentee before: YITENG PHARMACEUTICAL (SUZHOU) Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211105 Address after: 215124 No. 6, Baiyu Road, Suzhou Industrial Park, Suzhou, Jiangsu Patentee after: Suzhou sikro Pharmaceutical Co.,Ltd. Address before: 215000 building 10, biomedical industrial park, No. 218, Sangtian street, Suzhou Industrial Park, Suzhou pilot Free Trade Zone, Suzhou, Jiangsu Patentee before: Ruisi Pharmaceutical (Suzhou) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 215021 No. 6, Baiyu Road, Suzhou Industrial Park, Jiangsu Province Patentee after: YITENG PHARMACEUTICAL (SUZHOU) Co.,Ltd. Address before: 215124 No. 6, Baiyu Road, Suzhou Industrial Park, Suzhou, Jiangsu Patentee before: Suzhou sikro Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address |